RANKL Cancer Research Results

RANKL, Receptor Activator of Nuclear Factor κB Ligand: Click to Expand ⟱
Source:
Type:
RANKL (Receptor Activator of Nuclear Factor κB Ligand, formally known as TNFSF11)


-High expression of RANKL (or increased activity of the RANK pathway) has been linked to a higher tendency for bone metastasis, particularly in certain subtypes (e.g., estrogen receptor–negative cancers).
-Activation of this pathway may predict poor outcomes in specific settings, though the direct prognostic significance of RANKL levels still calls for additional clinical validation.
Scientific Papers found: Click to Expand⟱
8845- DIM,  I3C,    3,3′-Diindolylmethane and indole-3-carbinol: potential therapeutic molecules for cancer chemoprevention and treatment via regulating cellular signaling pathways
- Review, Var, NA
*BioAv↝, *BioAv↓, *BioAv↓, *AntiAg↑, *ROS↓, *AntiThr↑, *Stroke↓, *CYP1A1↑, *CYP1A2↑, *GSTs↑, *NQO1↑, AntiTum↑, AntiCan↑, TumAuto↓, Let-7↑, miR-34a↑, TumCMig↓, Apoptosis↑, MMP↓, mtDam↑, ROS↑, TumCCA↑, other↝, PSA↓, Dose↝, MMP2↓, MMP3↓, MMP9↓, EGFR↓, RAS↓, PI3K↓, Akt↓, mTOR↓, CDK4↓, cycD1/CCND1↓, P21↑, MDM2↓, TumCP↓, NF-kB↓, RANKL↓, PUMA↓, Wnt↓, MTA2↓, EZH2↓, AhR↓, PTEN↑, NOTCH1↓, IRAK1↓, p27/CDKN1B↓, CDKN1C/p57↓, CDC25↓, EGFR↓, Zeb1↓, FOXM1↓, SOX4↓, E-cadherin↑, uPA↓, uPAR↓,
1782- MLT,    Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities
- Review, Var, NA
AntiCan↑, Apoptosis↑, TumCP↓, TumCG↑, TumMeta↑, ChemoSideEff↓, radioP↑, ChemoSen↑, *ROS↓, *SOD↑, *GSH↑, *GPx↑, *Catalase↑, Dose∅, VEGF↓, Synergy↑, Hif1a↓, GLUT1↑, GLUT3↑, CAIX/CA9↑, P21↑, p27/CDKN1B↑, PTEN↑, Warburg↓, PI3K↓, Akt↓, NF-kB↓, cycD1/CCND1↓, CDK4↓, CycB/CCNB1↓, CDK4↓, MAPK↑, IGF-1R↓, STAT3↓, MMP9↓, MMP2↓, MMP13↓, E-cadherin↑, Vim↓, RANKL↓, JNK↑, Bcl-2↓, P53↑, Casp3↑, Casp9↑, BAX↑, DNArepair↑, COX2/PTGS2↓, IL6↓, IL8↓, NO↓, T-Cell↑, NK cell↑, Treg lymp↓, FOXP3↓, CD4+↑, TNF-α↑, Th1 response↑, BioAv↝, RadioS↑, OS↑,
1755- WBV,    Reduction of breast cancer extravasation via vibration activated osteocyte regulation
- Study, BC, NA
Dose∅, TumMeta↑, eff∅, Piezo1↑, COX2/PTGS2↑, RANKL↓, TumCG∅, tumCV∅, TumCI↓,

Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

ROS↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

CDC25↓, 1,   mtDam↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

CAIX/CA9↑, 1,   Warburg↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 2,   BAX↑, 1,   Bcl-2↓, 1,   Casp3↑, 1,   Casp9↑, 1,   MDM2↓, 1,   PUMA↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 2,   EGFR↓, 2,   IGF-1R↓, 1,   JNK↑, 1,   MAPK↑, 1,   mTOR↓, 1,   PI3K↓, 2,   PTEN↑, 2,   RAS↓, 1,   STAT3↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

EZH2↓, 1,   FOXM1↓, 1,   miR-34a↑, 1,   MTA2↓, 1,   other↝, 1,   SOX4↓, 1,   tumCV∅, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

TumAuto↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNArepair↑, 1,   P53↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK4↓, 3,   CDKN1C/p57↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 2,   P21↑, 2,   p27/CDKN1B↓, 1,   p27/CDKN1B↑, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Let-7↑, 1,   NOTCH1↓, 1,   Piezo1↑, 1,   TumCG↑, 1,   TumCG∅, 1,   TumCP↓, 2,   Wnt↓, 1,  

Migration(tgid=13) ⓘ

E-cadherin↑, 2,   MMP13↓, 1,   MMP2↓, 2,   MMP3↓, 1,   MMP9↓, 2,   TumCI↓, 1,   TumCMig↓, 1,   TumMeta↑, 2,   uPA↓, 1,   uPAR↓, 1,   Vim↓, 1,   Zeb1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

Hif1a↓, 1,   NO↓, 1,   VEGF↓, 1,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↑, 1,   GLUT3↑, 1,   MMP↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD4+↑, 1,   COX2/PTGS2↓, 1,   COX2/PTGS2↑, 1,   FOXP3↓, 1,   IL6↓, 1,   IL8↓, 1,   IRAK1↓, 1,   NF-kB↓, 2,   NK cell↑, 1,   PSA↓, 1,   T-Cell↑, 1,   Th1 response↑, 1,   TNF-α↑, 1,   Treg lymp↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AhR↓, 1,   RANKL↓, 3,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↝, 1,   ChemoSen↑, 1,   Dose↝, 1,   Dose∅, 2,   eff∅, 1,   RadioS↑, 1,   Synergy↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 2,   EZH2↓, 1,   FOXM1↓, 1,   IL6↓, 1,   PSA↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 2,   AntiTum↑, 1,   ChemoSideEff↓, 1,   OS↑, 1,   radioP↑, 1,  
Total Targets: 98

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

Catalase↑, 1,   GPx↑, 1,   GSH↑, 1,   GSTs↑, 1,   NQO1↑, 1,   ROS↓, 2,   SOD↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

AntiThr↑, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 2,   BioAv↝, 1,   CYP1A1↑, 1,   CYP1A2↑, 1,  

Functional Outcomes(tgid=23) ⓘ

Stroke↓, 1,  
Total Targets: 14

Scientific Paper Hit Count for: RANKL, Receptor Activator of Nuclear Factor κB Ligand
1 Diindolylmethane
1 Indole-3-carbinol
1 Melatonin
1 Whole Body Vibration
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1183  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page